- Conditions
- Safety, Tolerance
- Interventions
- Crystal Light (once serving), Liquid IV with amino acids (one serving), Liquid IV with amino acids (two servings), Liquid IV with amino acids (three servings)
- Dietary Supplement
- Lead sponsor
- University of Memphis
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 361–384
of 2,426
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
- Interventions
- JK07, Placebo
- Drug
- Lead sponsor
- Salubris Biotherapeutics Inc
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 51
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 45 more
- Conditions
- Acute Myocardial Infarction
- Interventions
- CSL112, Placebo
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,267 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Concord, California + 43 more
- Conditions
- Obstructed Defecation Syndrome (ODS)
- Interventions
- Botulinum Toxin-A, Normal Saline
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- COVID-19
- Interventions
- AS03, BNT162b2, BNT162b2 (B.1.1.529), BNT162b2 (B.1.351), BNT162b2 bivalent (wildtype and Omicron BA.1), BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5), CoV2 preS dTM [B.1.351], CoV2 preS dTM/D614, CoV2 preS dTM/D614+B.1.351, mRNA-1273, mRNA-1273.351, mRNA-1273.529, mRNA-1273.617.2, Sodium Chloride, 0.9%
- Drug · Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 1,270 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • San Diego, California • San Francisco, California + 15 more
- Conditions
- COVID-19, Lymphocytopenia
- Interventions
- CYT107, Placebo
- Drug
- Lead sponsor
- Revimmune
- Industry
- Eligibility
- 25 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- New York, New York • Houston, Texas
- Conditions
- Healthy Nutrition, Culinary Medicine, Sodium Excess
- Interventions
- Salt replacement seasoning (50% salt and 50% MSG) mix, Salt replacement seasoning (70% salt and 30% MSG) mix, NaCl (sodium chloride/table salt)
- Behavioral
- Lead sponsor
- Texas Tech University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 148 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Lubbock, Texas
- Conditions
- Cervical Dystonia
- Interventions
- incobotulinumtoxinA (Xeomin) (240 Units), incobotulinumtoxinA (Xeomin) (120 Units), Placebo
- Drug
- Lead sponsor
- Merz Pharmaceuticals GmbH
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 233 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Acute HIV Infection
- Interventions
- VRC07-523LS, PGT121.414.LS, Placebo, ART
- Biological · Other · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Aurora, Colorado • Atlanta, Georgia + 6 more
- Conditions
- Covid19
- Interventions
- Convalescent Plasma, Saline
- Biological
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 511 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 53
- States / cities
- Chandler, Arizona • Phoenix, Arizona • La Jolla, California + 41 more
- Conditions
- Hantaan Virus Disease, Puumala Virus
- Interventions
- Hantaan virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intradermal Delivery (ID), Hantaan virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intramuscular Delivery (IM), Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID), Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intramuscular Delivery (IM), Hantaan/Puumala (HTNV/PUUV) virus vaccines - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID), Hantaan/Puumala (HTNV/PUUV virus vaccines - Using the TriGrid Delivery System (TDS) for Intramusular Delivery (IM)
- Combination Product
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Juvenile Myelomonocytic Leukemia (JMML), Acute Lymphoblastic Leukemia (ALL), Lymphoma (Hodgkin's and Non-Hodgkin's)
- Interventions
- CliniMACS CD34+ Reagent System, Thiotepa, Cyclophosphamide, Alemtuzumab, Tacrolimus, Melphalan, Busulfan, Fludarabine, Methylprednisolone
- Device · Drug
- Lead sponsor
- Diane George
- Other
- Eligibility
- Up to 22 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Healthy Controls
- Interventions
- Ketamine, Normal saline
- Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 3
- States / cities
- Sacramento, California • New Haven, Connecticut • New York, New York
- Conditions
- Mixed Dyslipidemia
- Interventions
- ARO-APOC3, Placebo
- Drug
- Lead sponsor
- Arrowhead Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 353 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 15
- States / cities
- Beverly Hills, California • Northridge, California • Boca Raton, Florida + 11 more
- Conditions
- Multiple System Atrophy, Orthostatic Hypotension, Supine Hypertension
- Interventions
- Trimethaphan, Placebo
- Drug
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Posterior Vitreous Detachment
- Interventions
- Ultrasound examination
- Procedure
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Bone Loss, Aging
- Interventions
- placebo, denosumab
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 25 Years to 80 Years · Female only
- Enrollment
- 81 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Clostridium Difficile Infection
- Interventions
- Bezlotoxumab, Placebo, Antibacterial drug treatment (ABD)
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 21
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 18 more
- Conditions
- Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia, Multiple Myleoma, Non-Hodgkin Lymphoma
- Interventions
- Xembify, Placebo
- Drug
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 386 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 9
- States / cities
- Bullhead City, Arizona • Huntington Park, California • St. Petersburg, Florida + 6 more
- Conditions
- Healthy Adult Volunteers
- Interventions
- 0.075mg/kg TT301/MW189, 0.15mg/kg TT301MW189, 0.25mg/kg TT301/MW189, 0.30mg/kg TT301/MW189, Placebo
- Drug
- Lead sponsor
- Linda Van Eldik
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Epistaxis, Blood Pressure
- Interventions
- Oxymetazoline 0.05%, Phenylephrine 0.25%, Lidocaine 1% plus epinephrine 1:100,000, Bacteriostatic 0.9% NaCL
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Depemokimab, Placebo
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 981 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 42
- States / cities
- Bakersfield, California • Modesto, California • Newport Beach, California + 34 more
- Conditions
- Axial Spondyloarthritis, Nonradiographic Axial Spondyloarthritis, Nr-axSpA
- Interventions
- Certolizumab Pegol, Placebo
- Biological · Other
- Lead sponsor
- UCB BIOSCIENCES GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 317 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 32 more
- Conditions
- Obesity, Diabetes, Roux-en-Y Gastric Bypass
- Interventions
- Exendin-9,39, Saline
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 20 Years to 70 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota